Here’s Why FibroGen’s Stock Popped Friday

On Nov. 8, FibroGen (NASDAQ: FGEN) and its partner AstraZeneca (NYSE: AZN) reported safety and efficacy data from a pooled analysis of six large phase 3 clinical trials with roxadustat, a drug aimed at treating anemia in patients with chronic kidney disease (CKD).

In the non-dialysis-dependent group, the results incorporate the experience of nearly 4,300 patients. Just shy of 3,900 patients were included in the dialysis-dependent cohort. Large data sets like this are important for regulators such as the U.S. Food and Drug Administration to get comfortable with the drug's side-effect profile.

Source: Getty Images.

Continue reading

Source Fool.com